Compounds for use in treatment of mucostitis
The present invention provides methods for treating and/or preventing mucostitis with one or more compounds, or pharmaceutically acceptable salts thereof, disclosed herein, or compositions comprising the same.
1. A method of treating mucositis in a human comprising administering to the human in need thereof a therapeutically effective amount of a compound having the formula
or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 wherein the human is administered a pharmaceutical composition comprising the compound, or pharmaceutically acceptable salt thereof.
3. The method of claim 2 wherein the pharmaceutical composition further comprises another therapeutic agent.
4. The method of claim 3 wherein the another therapeutic agent is palifermin.
5. The method of claim 1 wherein the human also receives chemotherapy, radiation therapy, or both, for treatment of cancer.
6. The method of claim 2 wherein the pharmaceutical composition is administered orally, bucally, or sublingually.
7. The method of claim 2 wherein the pharmaceutical composition is a liquid.
8. The method of claim 2 wherein the pharmaceutical composition is a rinse.
9. The method of claim 8 wherein the compound in the rinse is at 1 mg/ml.
10. The method of claim 8 wherein the compound in the rinse is at 3 mg/ml.
11. The method of claim 8 wherein the compound in the rinse is at 10 mg/ml.
12. A method of treating mucositis in a human comprising administering orally, bucally, or sublingually to the human in need thereof a liquid pharmaceutical composition comprising 1 mg/ml of a compound having the formula
or a pharmaceutically acceptable salt thereof.
13. The method of claim 12 wherein the pharmaceutical composition is a rinse.
14. The method of claim 13 wherein the rinse comprises 3 mg/ml of the compound, or pharmaceutically acceptable salt thereof.
15. The method of claim 13 wherein the rinse comprises 10 mg/ml of the compound, or pharmaceutically acceptable salt thereof.
16. A method of treating mucositis in a human comprising administering orally, bucally, or sublingually to the human in need thereof a liquid pharmaceutical composition in the form of a rinse comprising 1 mg/ml of a compound having the formula
or a pharmaceutically acceptable salt thereof.